Therefore, coadministration of PARP inhibitors (olaparib, niraparib, rucaparib, and talazoparib) with TMZ or procarbazine is anticipated to ameliorate tumor cytotoxicity in the presence of MGMT. Here, MGMT is linked to neoplasm.